Literature DB >> 15329587

Comparative pharmacokinetics and pharmacodynamics of the new propofol prodrug GPI 15715 and propofol emulsion.

Jörg Fechner1, Harald Ihmsen, Dirk Hatterscheid, Christian Jeleazcov, Christine Schiessl, James J Vornov, Helmut Schwilden, Jürgen Schüttler.   

Abstract

BACKGROUND: GPI 15715 is a new water-soluble prodrug that is hydrolyzed to release propofol. The objectives of this crossover study in volunteers were to investigate the pharmacokinetics and pharmacodynamics of GPI 15715 in comparison with propofol emulsion.
METHODS: In two separate sessions, nine healthy male volunteers (19-35 yr, 70-86 kg) received GPI 15715 and propofol emulsion as a target controlled infusion over 60 min. In the first 20 min, the propofol target concentration increased linearly to 5 microg/ml. Subsequently, the targets were reduced to 3 microg/ml and 1.5 microg/ml for 20 min each. The plasma concentrations of GPI 15715 and propofol were measured from arterial and venous blood samples up to 24 h and pharmacokinetics were analyzed. The pharmacodynamic effect was measured by the median frequency of the power spectrum of the electroencephalogram, and a sigmoid model with effect compartment was fitted to the data.
RESULTS: Compared with propofol emulsion, propofol from GPI 15715 showed a different disposition function and especially larger volumes of distribution. The propofol effect site concentration for half maximum effect was 2.0 +/- 0.5 microg/ml for GPI 15715 and 3.0 +/- 0.7 microg/ml for propofol emulsion (P < 0.05). Propofol from GPI 15715 did not show a hysteresis between plasma concentration and effect.
CONCLUSIONS: Compared with propofol emulsion, propofol from GPI 15715 showed different pharmacokinetics and pharmacodynamics, particularly a higher potency with respect to concentration. These differences may indicate an influence of the formulation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15329587     DOI: 10.1097/00000542-200409000-00011

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  18 in total

1.  Preparation and anesthetic properties of propofol microemulsions in rats.

Authors:  Timothy E Morey; Jerome H Modell; Dushyant Shekhawat; Todd Grand; Dinesh O Shah; Nikolaus Gravenstein; Susan P McGorray; Donn M Dennis
Journal:  Anesthesiology       Date:  2006-06       Impact factor: 7.892

2.  Response: fospropofol: pharmacokinetics?

Authors:  Girish M Bengalorkar; K Bhuvana; N Sarala; Tn Kumar
Journal:  J Anaesthesiol Clin Pharmacol       Date:  2012-01

Review 3.  Pharmacokinetic and pharmacodynamic characteristics of medications used for moderate sedation.

Authors:  Tong J Gan
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

4.  Acute effects of thalamic deep brain stimulation and thalamotomy on sensorimotor cortex local field potentials in essential tremor.

Authors:  Ellen L Air; Elena Ryapolova-Webb; Coralie de Hemptinne; Jill L Ostrem; Nicholas B Galifianakis; Paul S Larson; Edward F Chang; Philip A Starr
Journal:  Clin Neurophysiol       Date:  2012-05-26       Impact factor: 3.708

5.  Subthalamic nucleus neurons are synchronized to primary motor cortex local field potentials in Parkinson's disease.

Authors:  Shoichi A Shimamoto; Elena S Ryapolova-Webb; Jill L Ostrem; Nicholas B Galifianakis; Kai J Miller; Philip A Starr
Journal:  J Neurosci       Date:  2013-04-24       Impact factor: 6.167

6.  Novel lipid and preservative-free propofol formulation: properties and pharmacodynamics.

Authors:  François Ravenelle; Sandra Gori; Dorothée Le Garrec; David Lessard; Laibin Luo; Dana Palusova; J Robert Sneyd; Damon Smith
Journal:  Pharm Res       Date:  2007-11-21       Impact factor: 4.200

7.  Motor System Interactions in the Beta Band Decrease during Loss of Consciousness.

Authors:  Nicole C Swann; Coralie de Hemptinne; Ryan B Maher; Catherine A Stapleton; Lingzhong Meng; Adrian W Gelb; Philip A Starr
Journal:  J Cogn Neurosci       Date:  2015-09-24       Impact factor: 3.225

8.  [Pharmacodynamics of two different propofol formulations].

Authors:  H Ihmsen; C Jeleazcov; J Schüttler; H Schwilden; F Bremer
Journal:  Anaesthesist       Date:  2006-06       Impact factor: 1.041

9.  Sedation and anesthesia options for pediatric patients in the radiation oncology suite.

Authors:  Eric A Harris
Journal:  Int J Pediatr       Date:  2010-05-13

10.  Monitored anesthesia care (MAC) sedation: clinical utility of fospropofol.

Authors:  Eric A Harris; David A Lubarsky; Keith A Candiotti
Journal:  Ther Clin Risk Manag       Date:  2009-12-29       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.